<DOC>
	<DOCNO>NCT02976012</DOCNO>
	<brief_summary>This phase I/II open label , randomize , interventional clinical trial . Study eye receive one preoperative intravitreal aflibercept injection ( IAI ) &lt; 21 day &gt; 7 day prior vitrectomy one intraoperative IAI end surgery follow randomization 1:1 ratio either 4 mandatory postoperative q4weeks IAI follow mandatory q8 week IAI 52 week follow-up ( q8 week Group ) 2 mandatory postoperative q4weeks IAI follow mandatory q16 week IAI 52 week follow-up ( q16 week Group ) .</brief_summary>
	<brief_title>Endolaserless Vitrectomy With Intravitreal IAI PDR-Related VH</brief_title>
	<detailed_description>This phase I/II open label , randomize , interventional clinical trial . Study eye receive one preoperative intravitreal aflibercept injection ( IAI ) &lt; 21 day &gt; 7 day prior vitrectomy one intraoperative intravitreal aflibercept end surgery follow randomization 1:1 ratio either 4 mandatory postoperative q4weeks IAI follow mandatory q8 week IAI 52 week follow-up ( q8 week Group ) 2 mandatory postoperative q4weeks IAI follow mandatory q16 week IAI 52 week follow-up ( q16 week Group ) . Follow-up visit occur 1 day 1-2 week , 4 week postoperatively every 4 week first postoperative IAI 52 week . One preoperative visit every postoperative visit ( except day one postoperatively ) include ETDRS Best Corrected Visual Acuity ( BCVA ) , Intraocular Pressure ( IOP ) measurement , Slit lamp biomicroscopy , Indirect ophthalmoscopy , Heidelberg Spectralis Spectral Domain Optical Coherence Tomography ( SD-OCT ) ( OCT preoperative visit ) evaluation systemic ocular adverse event . Seven standard field photograph Optos wide-field fluorescein angiography perform postoperative visit 4 , 16 , 28 , 40 , 52 week . Humphrey visual field ( HVF ) test ( 30-2 60-4 test pattern ) perform postoperative visit 4 52 week . Preoperative B scan echography require standard care ( SOC ) ass macular traction , non-macular traction , retinal detachment vitreous hemorrhage ( VH ) . Identification traction macular detachment exclude patient study .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Vitreous Hemorrhage</mesh_term>
	<criteria>1 . Adults age &gt; 18 year Diabetes Mellitus 2 . PDR relate vitreous hemorrhage another cause 3 . BCVA Vision LP well 4 . Investigator determination vitrectomy indicate PDRrelated vitreous hemorrhage 5 . Willing able comply clinic visit studyrelated procedure 6 . Provide HIPPA sign informed consent prior study procedure 1 . A condition per investigator opinion , would preclude participation study ( unstable medical status , cardiovascular disease , glycemic control , inability follow etc . ) 2 . Participation investigational trial within 30 day enrollment 3 . Known allergy IAI 4 . Systemic antiVEGF proVEGF treatment within 4 month enrollment 5 . For woman childbearing age , pregnant lactate intend become pregnant within next 3 year 6 . History PRP peripheral retinal cryopexy peripheral retinopexy reason study eye 7 . History vitrectomy study eye 8 . History evidence rhegmatogenous retinal detachment study eye 9 . Evidence traction retinal detachment involve threatening central macula study eye 10 . Exam evident external ocular infection ( i.e . conjunctivitis , significant blepharitis , chalazion etc ) 11 . Intravitreal antiVEGF injection study eye &lt; 4weeks enrollment . 12 . Pregnant breastfeed woman 13 . Sexually active men* woman childbearing potential** unwilling practice adequate contraception study ( adequate contraceptive measure include stable use oral contraceptive prescription pharmaceutical contraceptive 2 menstrual cycle prior screen ; intrauterine device [ IUD ] ; bilateral tubal ligation ; vasectomy ; condom plus contraceptive sponge , foam , jelly , diaphragm plus contraceptive sponge , foam , jelly ) *Contraception require men document vasectomy . **Postmenopausal woman must amenorrheic least 12 month order consider child bear potential . Pregnancy test contraception require woman document hysterectomy tubal ligation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Proliferative Diabetic Retinopathy</keyword>
	<keyword>Aflibercept</keyword>
	<keyword>Vitreous Hemorrhage</keyword>
</DOC>